Actively Recruiting
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
Led by University Hospital, Strasbourg, France · Updated on 2026-01-15
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research investigates cases of disseminated borreliosis, an infection caused by Borrelia burgdorferi sl. and Borrelia miyamotoi, in patients who have received treatment with anti-CD20 monoclonal antibodies. The study aims to clinically, biologically, radiologically, and pharmacologically describe these cases to better understand the infection among this specific patient group in France. The study is observational and collects data from patients who developed disseminated borreliosis within 24 months after receiving anti-CD20 therapy between January 2010 and July 2025. It does not involve administering treatments but focuses on monitoring and describing the disease's presentation and course. Participants will be evaluated for up to 12 months, during which researchers will document the clinical presentation of borreliosis cases. The study involves collecting medical information and biological data to characterize the infection. There is no intervention, and participants' usual medical care continues throughout the observation period.
CONDITIONS
Brief Title
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Minor or adult subject
- Confirmed disseminated borreliosis by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi)
- Diagnosis within 24 months of receiving anti-CD20 monoclonal antibody treatment between January 1, 2010, and July 30, 2025
You will not qualify if you...
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants are observed to describe the clinical presentation of disseminated borreliosis occurring in patients receiving anti-CD20 therapy.
Trial Site Locations
Total: 1 location
1
Laboratoire de Bactériologie - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
P
Pierre BOYER, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here